Choline
Also sold as: Choline · Citicoline · CDP-choline · Alpha-GPC · Phosphatidylcholine
An essential nutrient used to build cell membranes, acetylcholine and methyl donors. Nutritional repletion and form-specific cognitive trials are different use cases; more choline does not reliably improve performance.
Focus Energy
Community
Not enough ratings yet: 0 of 10
Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.
Research
- Focus: Small form-specific studies suggest selected memory/cognitive benefits; age, baseline status and sponsorship limit transfer to healthy young users.
- Energy: Exercise RCTs do not consistently improve aerobic performance, power, strength or fatigue despite plausible acetylcholine mechanisms.
REALITY CHECK // Bitartrate, citicoline and alpha-GPC are not interchangeable evidence packages. Small memory signals do not establish a general brain-repair treatment, exercise trials are largely null, and the source mistakenly extracted adequate intakes as upper limits in its numeric metadata.
Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.
Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.
Check your bottle
Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.
Enter the amount from your label to see the result.
How it was studied
UPPER LIMIT // EFSA adequate intake is 400 mg/day for adults; EFSA has not established a UL. US IOM adequate intakes are 550 mg/day for men, 425 for women, 450 in pregnancy and 550 in lactation. The adult US UL is 3500 mg/day total choline, based on hypotension/fishy odor. Adequate intake values are not upper limits.
Summary
Correcting deficiency-related fatty liver is supported in controlled depletion and parenteral-nutrition contexts, not as a general fat-loss treatment. Citicoline memory data in older adults and acute alpha-GPC cognitive data are preliminary. Anxiety was omitted as a goal because memory/behavior findings in older impaired adults do not establish an anxiety benefit.
Mechanism
Choline contributes to phosphatidylcholine membranes and acetylcholine synthesis, and oxidation to betaine supports homocysteine remethylation. Microbial conversion to TMA/TMAO provides a plausible safety pathway, but observational associations do not prove cardiovascular harm from every choline form.
Typical studied dose
A producer-sponsored RCT in healthy older adults, approximately 50–85 years, used 500 mg citicoline/day for 12 weeks. A small prenatal feeding RCT compared total intake of 930 versus 480 mg choline/day during the third trimester (n=20 offspring follow-up). Alpha-GPC had an acute study but the extracted dose is not specified. Trial exposures are not universal instructions.
Upper limit
EFSA adequate intake is 400 mg/day for adults; EFSA has not established a UL. US IOM adequate intakes are 550 mg/day for men, 425 for women, 450 in pregnancy and 550 in lactation. The adult US UL is 3500 mg/day total choline, based on hypotension/fishy odor. Adequate intake values are not upper limits.
Popular stacks with Choline
Not enough stack data yet. A combination with Choline appears here once 5 people rate the same set.
Forms and label traps
| Form on label | Active content | Studied range / day | Absorption & GI tolerance | Verdict |
|---|---|---|---|---|
| Choline bitartrate (~41% choline) Best for: Nutritional choline accounting. |
41% elemental / active | no comparable trial range | Provides peripheral choline; the dossier does not establish comparable cognitive efficacy to citicoline/alpha-GPC. Usually tolerated; higher intake can produce fishy odor and GI symptoms. |
Caution [SOURCE // CHECK_LABEL] 41% is an approximate source-supplied fraction marked unverified, not a product assay. No form-specific elemental trial range is extracted. |
| Choline chloride (~74% choline) Best for: Understanding a high choline fraction on a label. |
74% elemental / active | no comparable trial range | Nutritional/peripheral source; cognitive equivalence is unproved. GI symptoms and odor may occur at higher intakes. |
Caution [SOURCE // CHECK_LABEL] No trial interval is supplied. |
| Citicoline / CDP-choline (~18% choline) Best for: Comparing the compound exposure used in an older-adult memory RCT. |
Extract weight · ~18% marker | 500–500 mg | Oral administration raises plasma choline and uridine; clinical findings remain population-specific. Generally well tolerated in the cited trials. |
Studied standard [SOURCE // FORM_SPECIFIC] Calculator compares 500 mg citicoline compound with the 500 mg/day trial exposure; approximately 18% is the choline fraction, not a second multiplication for the trial comparison. |
| Alpha-GPC (~40% choline in pure compound) Best for: Form-specific cognitive evidence and label accounting. |
40% elemental / active | no comparable trial range | Cholinergic precursor with selected acute cognitive findings; sustained enhancement is unproved. Usually tolerated in studies; headache/irritability reports are partly anecdotal. |
Caution [SOURCE // CHECK_LABEL] 40% is an approximate source-supplied fraction; diluted alpha-GPC powders require their own purity specification. The acute trial dose is not extracted. |
| Phosphatidylcholine / lecithin (variable composition) Best for: Recognizing that lecithin mass is not pure choline mass. |
Unstandardized: active content unknown | no comparable trial range | Slower choline release; human homocysteine data exist. Often well tolerated; source-specific composition varies. |
Caution [SOURCE // CHECK_LABEL] No universal choline fraction or trial dose is available for mixed lecithin products. |
Common label traps
- TRAP_01 // EVERY CHOLINE FORM HAS THE SAME BRAIN EFFECT
Nutritional sources and cognitive trial formulations differ. Approximate choline fractions do not establish equal clinical effects. - TRAP_02 // MORE CHOLINE MEANS MORE MEMORY
Evidence is population/form-specific; excess can cause hypotension, odor and GI effects. Adequate intake is not an escalating performance target. - TRAP_03 // LIPOTROPIC MEANS FAT LOSS OR STROKE REPAIR
Reversing deficiency-related fatty liver is not evidence of losing body fat. A large acute-stroke RCT did not improve overall function; this is medical care, not a self-treatment indication.
Other outcomes studied
Outside the five leaderboard goals. Same evidence levels as above.
- DEFICIENCY-RELATED FATTY LIVER Moderate · benefit
Human parenteral-nutrition interventions and controlled depletion support repletion of deficiency-related liver changes. This is not established treatment for well-nourished adults or general weight loss; animal deficient-diet models are not directly transferable.
PMID 7590654 PMID 19906248 PMID 38257153 - OLDER ADULT MEMORY Limited · benefit
The Cochrane review found short-term memory/behavior signals in older adults with chronic cerebral cognitive/vascular disorders, but evidence was low-quality/heterogeneous and long-term benefit unproved. This does not establish anxiety treatment.
PMID 15846601 PMID 11034681 PMID 41426989 - HEALTHY OLDER ADULT MEMORY Limited · benefit
A single manufacturer-sponsored double-blind RCT in adults roughly 50–85 years found improved episodic-memory tasks with 500 mg citicoline/day for 12 weeks; independent replication is needed.
PMID 33978188 - ACUTE COGNITIVE TESTS Limited · benefit
A small alpha-GPC RCT in healthy young men improved selected tests after an acute dose. It does not establish durable cognition or strength benefits; dose was not extracted.
PMID 39683633 - PRENATAL DEVELOPMENT Limited · benefit
A controlled-feeding RCT comparing 930 versus 480 mg/day total choline during the third trimester found better offspring sustained attention at age seven (SAT p=.02), but only n=20 were followed. A separate study concerns alcohol-exposed pregnancies; neither result supports unsupervised megadosing.
PMID 34962672 PMID 34942330 - ACUTE ISCHEMIC STROKE Limited · no benefit
A multicenter RCT found no overall functional advantage versus placebo on Barthel/NIHSS outcomes. A post-hoc severe-stroke subgroup signal is not confirmatory; supplements are not a replacement for stroke care.
PMID 10582983 - EXERCISE PERFORMANCE Limited · no benefit
Trials in healthy/trained adults found no consistent aerobic, power/work or fatigue benefit. Plasma depletion in prolonged exercise is not proof supplementation improves results; multi-ingredient products prevent attribution.
PMID 12502178 PMID 28222577 PMID 7674870 - HOMOCYSTEINE Limited · benefit
Phosphatidylcholine lowered fasting/post-methionine homocysteine in healthy men. This is a biomarker outcome without demonstrated reduction in cardiovascular events; postmenopausal status data add context, not causality.
PMID 16002808 PMID 22172554 - TMA/TMAO SAFETY SIGNAL Limited · makes it worse
Microbial metabolism and observational vascular associations raise questions, but do not establish that a specific choline supplement causes cardiovascular disease. Long-term causal clinical evidence remains uncertain.
PMID 21475195 PMID 30362023 PMID 23614584
Reader questions
Do I need citicoline instead of bitartrate?
That depends on the question. Meeting nutritional choline needs and matching a form-specific cognitive trial are different aims; no universal cognitive superiority is established for every person.
Is 550 mg the choline upper limit?
No. In the source, 550 mg/day is the US adequate intake for adult men and lactation. The adult US total-intake UL is 3500 mg/day; EFSA has no established UL.
Does choline cause depression or vascular disease?
Mood reports are mostly anecdotal, while TMAO/vascular findings are largely observational or mechanistic. Neither proves the same risk for every form and user, but new symptoms or high baseline risk need individualized review.
Stack interactions
- Caution Psychiatric medicines and mood disorders [CAUTION // EVIDENCE_CONTEXT]
Reports of lower mood/irritability with high-dose cholinergics are anecdotal; clinical magnitude and causality are unverified. Review symptoms rather than self-escalating. - Caution Racetams [CAUTION // EVIDENCE_CONTEXT]
Community headache/brain-fog relief claims rely on reports and cholinergic reasoning. The dossier does not establish a clinical requirement for a choline stack. - Caution Folate and vitamin B12 [CAUTION // EVIDENCE_CONTEXT]
Shared one-carbon metabolism can alter nutritional requirements; the cited work is context-specific, not proof every user needs combined supplementation.
PMID 31473512 PMID 41170010 - Caution Betaine and methionine [CAUTION // EVIDENCE_CONTEXT]
Choline oxidation to betaine supports remethylation of homocysteine. Biomarker improvement does not establish prevention of vascular events.
PMID 16002808
Red flags: interactions and who should avoid it
Interactions
Mood changes with high-dose cholinergics and racetam headache relief are community reports/mechanistic hypotheses rather than validated interaction trials. Folate, B12, betaine and methionine share one-carbon metabolism; no universal stack is established. The proposed methotrexate/choline connection is unverified in this dossier.
Avoid or ask a doctor first if
Trimethylaminuria can worsen odor with high choline exposure. Pregnancy/lactation need individualized nutritional assessment rather than megadosing. Mood disorders/psychiatric medicines, kidney disease and high cardiovascular risk merit review. Excess may cause hypotension, sweating, salivation, nausea, diarrhea and fishy odor; long-term alpha-GPC safety and observational vascular signals remain unresolved.
Sources (PubMed, 18)
- A randomized efficacy trial of citicoline in patients with acute ischemic stroke.
PMID 10582983 · 1999 · randomized controlled trialA multicenter RCT found no overall functional advantage versus placebo on Barthel/NIHSS outcomes. A post-hoc severe-stroke subgroup signal is not confirmatory; supplements are not a replacement for stroke care.
- Effect of oral CDP-choline on plasma choline and uridine levels in humans.
PMID 10974208 · 2000 · randomized controlled trialCalculator compares 500 mg citicoline compound with the 500 mg/day trial exposure; approximately 18% is the choline fraction, not a second multiplication for the trial comparison.
- Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly.
PMID 11034681 · 2000 · systematic reviewThe Cochrane review found short-term memory/behavior signals in older adults with chronic cerebral cognitive/vascular disorders, but evidence was low-quality/heterogeneous and long-term benefit unproved. This does not establish anxiety treatment.
- Choline ingestion does not modify physical or cognitive performance.
PMID 12502178 · 2002 · randomized controlled trialTrials in healthy/trained adults found no consistent aerobic, power/work or fatigue benefit. Plasma depletion in prolonged exercise is not proof supplementation improves results; multi-ingredient products prevent attribution.
- Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly.
PMID 15846601 · 2005 · meta-analysisThe Cochrane review found short-term memory/behavior signals in older adults with chronic cerebral cognitive/vascular disorders, but evidence was low-quality/heterogeneous and long-term benefit unproved. This does not establish anxiety treatment.
- Choline supplemented as phosphatidylcholine decreases fasting and postmethionine-loading plasma homocysteine concentrations in healthy men.
PMID 16002808 · 2005 · randomized controlled trialPhosphatidylcholine lowered fasting/post-methionine homocysteine in healthy men. This is a biomarker outcome without demonstrated reduction in cardiovascular events; postmenopausal status data add context, not causality.
- Citicoline: pharmacological and clinical review, 2006 update.
PMID 17171187 · 2006 · reviewCalculator compares 500 mg citicoline compound with the 500 mg/day trial exposure; approximately 18% is the choline fraction, not a second multiplication for the trial comparison.
- Choline: an essential nutrient for public health.
PMID 19906248 · 2009 · reviewHuman parenteral-nutrition interventions and controlled depletion support repletion of deficiency-related liver changes. This is not established treatment for well-nourished adults or general weight loss; animal deficient-diet models are not directly transferable.
- Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
PMID 21475195 · 2011 · catalogued study; design described in outcome contextMicrobial metabolism and observational vascular associations raise questions, but do not establish that a specific choline supplement causes cardiovascular disease. Long-term causal clinical evidence remains uncertain.
- Choline supplementation and measures of choline and betaine status: a randomised, controlled trial in postmenopausal women.
PMID 22172554 · 2012 · randomized controlled trialPhosphatidylcholine lowered fasting/post-methionine homocysteine in healthy men. This is a biomarker outcome without demonstrated reduction in cardiovascular events; postmenopausal status data add context, not causality.
- Acute ingestion of neuromuscular enhancement supplements do not improve power output, work capacity, and cognition.
PMID 28222577 · 2018 · randomized controlled trialTrials in healthy/trained adults found no consistent aerobic, power/work or fatigue benefit. Plasma depletion in prolonged exercise is not proof supplementation improves results; multi-ingredient products prevent attribution.
- Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
PMID 33978188 · 2021 · randomized controlled trialA single manufacturer-sponsored double-blind RCT in adults roughly 50–85 years found improved episodic-memory tasks with 500 mg citicoline/day for 12 weeks; independent replication is needed.
- The impact of micronutrient supplementation in alcohol-exposed pregnancies on reaction time responses of preschoolers in Ukraine.
PMID 34942330 · 2022 · randomized controlled trialA controlled-feeding RCT comparing 930 versus 480 mg/day total choline during the third trimester found better offspring sustained attention at age seven (SAT p=.02), but only n=20 were followed. A separate study concerns alcohol-exposed pregnancies; neither result supports unsupervised megadosing.
- Prenatal choline supplementation improves child sustained attention: A 7-year follow-up of a randomized controlled feeding trial.
PMID 34962672 · 2022 · randomized controlled trialA controlled-feeding RCT comparing 930 versus 480 mg/day total choline during the third trimester found better offspring sustained attention at age seven (SAT p=.02), but only n=20 were followed. A separate study concerns alcohol-exposed pregnancies; neither result supports unsupervised megadosing.
- A Narrative Review on Maternal Choline Intake and Liver Function of the Fetus and the Infant; Implications for Research, Policy, and Practice.
PMID 38257153 · 2024 · reviewHuman parenteral-nutrition interventions and controlled depletion support repletion of deficiency-related liver changes. This is not established treatment for well-nourished adults or general weight loss; animal deficient-diet models are not directly transferable.
- Pharmacokinetics of 14C CDP-choline.
PMID 6412727 · 1983 · catalogued study; design described in outcome contextCalculator compares 500 mg citicoline compound with the 500 mg/day trial exposure; approximately 18% is the choline fraction, not a second multiplication for the trial comparison.
- Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation.
PMID 7590654 · 1995 · catalogued study; design described in outcome contextHuman parenteral-nutrition interventions and controlled depletion support repletion of deficiency-related liver changes. This is not established treatment for well-nourished adults or general weight loss; animal deficient-diet models are not directly transferable.
- Effect of choline supplementation on fatigue in trained cyclists.
PMID 7674870 · 1995 · randomized controlled trialTrials in healthy/trained adults found no consistent aerobic, power/work or fatigue benefit. Plasma depletion in prolonged exercise is not proof supplementation improves results; multi-ingredient products prevent attribution.
Community comments
No approved comments yet. Comments are held for moderation.